A Cost-Utility Model Comparing Azilect ® (Rasagiline) with Standard Care and Entacapone in the Treatment of Parkinsonian Patients with Motor Fluctuations under Levodopa in Finland
HomePublicationsA Cost-Utility Model Comparing Azilect ® (Rasagiline) with Standard Care and Entacapone in the Treatment of Parkinsonian Patients with Motor Fluctuations under Levodopa in Finland
A Cost-Utility Model Comparing Azilect ® (Rasagiline) with Standard Care and Entacapone in the Treatment of Parkinsonian Patients with Motor Fluctuations under Levodopa in Finland
